现代中西医结合杂志
現代中西醫結閤雜誌
현대중서의결합잡지
Modern Journal of Integrated Traditional Chinese and Western Medicine
2015年
27期
2980-2982
,共3页
扶正抑瘤汤剂%结直肠癌%化疗%免疫力
扶正抑瘤湯劑%結直腸癌%化療%免疫力
부정억류탕제%결직장암%화료%면역력
Fuzheng Yiliu decoction%colorectal cancer%chemotherapy%immunity
目的：观察扶正抑瘤汤对结直肠癌化疗后患者机体免疫力的影响。方法将76例结直肠癌化疗后患者按照随机数字表法分为对照组和观察组，每组38例。对照组给予金复康口服液口服，观察组给予扶正抑瘤汤剂口服，2组均连续治疗4周。评估2组治疗前后乏力、纳差、胃脘痞闷、口干、便干积分，检测治疗前后肿瘤坏死因子－α（ TNF－α）、白细胞介素－1β（IL－1β）、IL－6及T淋巴细胞亚群水平。结果2组治疗后乏力、纳差、胃脘痞闷、口干、便干积分均较治疗前明显升高（P均＜0．05），且观察组升高程度较对照组更显著（P均＜0．05）。2组治疗后TNF－α及CD3＋、CD4＋、CD8＋、CD4＋／CD8＋水平均较治疗前明显升高（P均＜0．05），IL－1β、IL－6水平均较治疗前明显降低（P均＜0．05），且观察组升高或降低程度均明显优于对照组（ P均＜0．05）。结论扶正抑瘤汤能明显缓解结直肠癌化疗后患者的不适症状，增强患者机体免疫力，值得临床深入研究运用。
目的：觀察扶正抑瘤湯對結直腸癌化療後患者機體免疫力的影響。方法將76例結直腸癌化療後患者按照隨機數字錶法分為對照組和觀察組，每組38例。對照組給予金複康口服液口服，觀察組給予扶正抑瘤湯劑口服，2組均連續治療4週。評估2組治療前後乏力、納差、胃脘痞悶、口榦、便榦積分，檢測治療前後腫瘤壞死因子－α（ TNF－α）、白細胞介素－1β（IL－1β）、IL－6及T淋巴細胞亞群水平。結果2組治療後乏力、納差、胃脘痞悶、口榦、便榦積分均較治療前明顯升高（P均＜0．05），且觀察組升高程度較對照組更顯著（P均＜0．05）。2組治療後TNF－α及CD3＋、CD4＋、CD8＋、CD4＋／CD8＋水平均較治療前明顯升高（P均＜0．05），IL－1β、IL－6水平均較治療前明顯降低（P均＜0．05），且觀察組升高或降低程度均明顯優于對照組（ P均＜0．05）。結論扶正抑瘤湯能明顯緩解結直腸癌化療後患者的不適癥狀，增彊患者機體免疫力，值得臨床深入研究運用。
목적：관찰부정억류탕대결직장암화료후환자궤체면역력적영향。방법장76례결직장암화료후환자안조수궤수자표법분위대조조화관찰조，매조38례。대조조급여금복강구복액구복，관찰조급여부정억류탕제구복，2조균련속치료4주。평고2조치료전후핍력、납차、위완비민、구간、편간적분，검측치료전후종류배사인자－α（ TNF－α）、백세포개소－1β（IL－1β）、IL－6급T림파세포아군수평。결과2조치료후핍력、납차、위완비민、구간、편간적분균교치료전명현승고（P균＜0．05），차관찰조승고정도교대조조경현저（P균＜0．05）。2조치료후TNF－α급CD3＋、CD4＋、CD8＋、CD4＋／CD8＋수평균교치료전명현승고（P균＜0．05），IL－1β、IL－6수평균교치료전명현강저（P균＜0．05），차관찰조승고혹강저정도균명현우우대조조（ P균＜0．05）。결론부정억류탕능명현완해결직장암화료후환자적불괄증상，증강환자궤체면역력，치득림상심입연구운용。
Objective It is to observe the influence of Fuzheng Yiliu decoction ( FZYLD) on the immunity of patients with colorectal cancer after chemotherapy.Methods 76 patients with colorectal cancer after chemotherapy were randomly divided into control group and observation group with 38 cases in each group.The patients were treated with Jinfukang oral solution in the control group and with FZYLD in the observation group, 4 weeks for treatment in both groups.Before and after treatment, the clinical symptoms score were assessed, and the levels of TNF-α, IL-1β, IL-6 and T lymphocyte subsets were detec-ted.Results After treatment, the symptoms score such as fatigue, anorexia, abdominal distension, dry mouth and constipation in both groups were markedly higher than before treatment (all P<0.05), and the observation group was more pronounced than the control group ( all P<0.05);the levels of TNF-α, CD3 +, CD4 +, CD8+and the value of CD4 +/CD8 +in both groups were markedly higher than before treatment(all P<0.05), and the levels of IL-1βand IL-6 was markedly lower than before treatment (all P<0.05), and the observation group was more pronounced than the control group (all P<0.05). Conclusion FZYLD can effectively alleviate the uncomfortable symptom of patients with colorectal cancer after chemotherapy, strengthen the immunity of patients, it is worthy of further research and development.
